U.S. markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
74.07-0.06 (-0.08%)
At close: 4:00PM EDT

74.07 0.00 (0.00%)
After hours: 4:43PM EDT

Sign in to post a message.
  • L
    Larry
    The impact of Semaglutide is extremely muted.
    Given the extent of the western world's obesity problem and the statement that this is deemed the first ever drug to provide a 15-20% weight reduction compared to placebo is astonishing.

    I've held NVO since 2017 and it has been a great return, but the current share price doesn't reflect the potential, the quality of the company with over 30% margins, a lump of cash and no effective net debt. The company keeps increasing retained earnings and handing out generous dividends more than covered by free cash flow.
    Why oh why are people not latching onto this or are they all into stupid meme stocks?
    Anyhow I'm added to my holding making it over 4% of my wad.
    Surely it will be recognised at some point, no? -- Or is there something missing here?
  • L
    Larry
    Up she goes - breaking past $70 today. Is the market finally recognising something?
  • j
    jg
    I have been on first Victoza and then Ozempic for 1 1/2 years. i have lost 80 plus pounds. Yes it has been approved /to be sold for weight loss only in Europe and Canada but what is holding it back is US approval. Even if it gets approval in the US for the same it has a way to go. What is worrying insitutional buying is whether insurance companies will pay for this. They pay if the patient is a diabetic and needs weight loss but not for weight loss only. That is going to be alot of patients wanting their insurance to pay $1000 month for the drug. joanne
  • A
    Alexander
    NOVO applied to test the oral form of the Semagultide in a 3a trail. Chart looks good as well.
  • H
    Harvey
    Lilly and Sanofi have bigger fish to fry and are moving out of the diabetes space, just look at their
    R&D projects.
  • A
    Alexander
    The delay on the 2.4 obesity approval app, should only delay things a quarter or two. still holding.
  • p
    peachbacks
    100 m obese In Usa. Assume 10m take the drug. Assume $500 per year net earnings per patient post-tax. You get large #. Assume no other global sales. Assume NVO and Lilly are way ahead of others. The mean weight loss of 15% is 30 lbs in a 200 start. Assume Usa approval in 8 months and EU in 12 months. Assume this is chronic indefinite therapy. Make your own market #'s. Risks are there even in the holy grail of the diet market.
  • N
    NHJ
    Sorry for the drop today guys, I bought earlier today..
  • A
    Alexander
    Well I'm in, can't believe this ghostown on a board. Going to fill more on Monday. Love the expansion in production, buyback and phase 1. No more Fatty's here we come!
  • M
    Mark
    im really surprised this didnt take off a bit more after the obesity study.
  • M
    Mark
    phase 1 is early but the results are promising. if this truly works then the potential is scary...scary good.
  • T
    Thomas
    what are total annual sales of industry-best Xeris Gvoke HypoPen? asking for a friend (meifud)
  • C
    Cfsaxny
    Renaissance technologies top holding, NVO.
    Bullish
  • p
    peachbacks
    This is going to be prescribed off label as you read this- obesity is worse than face wrinkles; Botox. The broad expansion will be when insurance starts covering some of the cost for weightloss.
    Neutral
  • L
    LeoD
    Can anyone shed light on 8.16 % AH rise no word on finance channels there was interview near noon with Laz. Maybe a delayed reaction to something he said about new products?
    Bullish
  • H
    Hguy
    $AEZS conversation
    $AEZS $NVO new 2019 share repurchase programme
    The Board of Directors has approved a new share repurchase programme of up to DKK 15 billion to be executed
    during the coming 12 months. The total programme may be reduced in size, in case of a significant bolt-on
    acquisition during 2019.
    https://www.novonordisk.com/bin/getPDF.2233033.pdf
  • b
    boohoo
    I would like to see a company like Merck, Johnson & Johnson buy them out.
    Bullish
  • D
    David
    In case anyone isn't aware here, check out little EMIS. Novo (NVO) contracts with them to use their pill technology for the recently announced very positive ph3 data, and for the next 9 ph3 trials anticipated to complete and have data released over the course of 2018.
  • k
    ken.
    $MNKD conversation
    $sny and $nvo Don't sweat this actors acting before the house special committee on aging discussing diabetes research funding. Likely helps you. This video was published by mnkd. Since released 10 mos ago sales of poor selling Afrezza, that's not a substitute for long acting insulin and hasn't yet started FDA mandated 8-10K patient FDA, have continued their downward spiral. Since it's a mnkd video one must wonder what actor received to give the brief Afrezza bleeb that had nothing to do with focus of committee.

    Underwater mnkd pumpers are desperate and afraid.
    House of Cards actor, Paul Sparks, speaks to Congress on diabetes funding and makes mention of his experience with inhaled insulin. JDRF Children’s Congress ...
    House of Cards actor, Paul Sparks, speaks to Congress on diabetes funding and makes mention of his experience with inhaled insulin. JDRF Children’s Congress ...
    www.youtube.com